Clincosm LogoSign in Get a demo

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00099801
Collaborator
(none)
13.9
Duration (Months)

Study Details

Study Description

Brief Summary

The safety and efficacy of FTY720 is being evaluated in patients who receive a kidney transplant.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
Study Start Date :
Jan 1, 2005
Actual Primary Completion Date :
Mar 1, 2006
Actual Study Completion Date :
Mar 1, 2006

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patients undergoing their first kidney transplant

    • Male or female age 18 to 65 years

    Exclusion Criteria:
    • Patients in need of second kidney transplant or multi-organ transplants.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Novartis Pharmaceuticals

    Investigators

    • Study Director: Novartis, Novartis

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00099801
    Other Study ID Numbers:
    • CFTY720A2307
    First Posted:
    Dec 21, 2004
    Last Update Posted:
    Jun 7, 2017
    Last Verified:
    Jun 1, 2017
    Keywords provided by , ,
    Kidney, Transplantation, Rejection, Immunosuppression
    Additional relevant MeSH terms:
    Fingolimod Hydrochloride

    Study Results

    No Results Posted as of Jun 7, 2017